Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY

08 Aug 2025 CW Team

Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.

Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.

Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.

Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.

To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.

Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”

CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”

Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Infrastructure Urban

30 Sep 2025

PM Modi Launches Rs 1.22 Trillion Development Projects in Banswara

Prime Minister Shri Narendra Modi inaugurated and laid the foundation stone for development works worth over Rs 1.22 trillion in Banswara, Rajasthan, on the fourth day of Navratri. During his visit to the sacred land of Maa Tripura Sundari and Maa Mahi, the Prime Minister paid homage to the region’s spiritual heritage and highlighted the resilience of India’s tribal communities, inspired by the legacy of Mahayogi Govind Guru Ji.Shri Modi emphasised energy generation as a national priority, announcing power projects exceeding Rs 900 billion across Rajasthan, Madhya Pradesh, Andhra Pradesh, ..

Infrastructure Urban

30 Sep 2025

GeM Launches Campaign to Boost Transparency and Fair Trade

The Government e-Marketplace (GeM) has launched a special campaign during Vigilance Awareness Week titled “GeM Ki Sunien, Satark Rahein, Zimmedar Banein,” reinforcing its commitment to transparency, integrity, and ethical practices in public procurement.The initiative aims to educate and empower buyers to adopt best practices and comply with rules while enabling sellers—including last-mile entrepreneurs, startups, and micro and small enterprises (MSEs) from Tier-2 and Tier-3 cities—to access secure and transparent opportunities. GeM’s safeguards, such as red-flag alerts, structured b..

Infrastructure Urban

30 Sep 2025

DoT, FIU-IND Join Forces to Curb Telecom-Based Frauds

The Department of Telecommunications (DoT) and the Financial Intelligence Unit-India (FIU-IND) have signed a comprehensive Memorandum of Understanding (MoU) to strengthen information sharing and coordination, marking a major step in India’s fight against telecom misuse in cyber-crimes and financial fraud.The MoU was signed by Shri Sanjeev Kumar Sharma, Deputy Director General (AI & Digital Intelligence Unit – DIU), DoT, and Shri Amit Mohan Govil, Director, FIU-IND, in the presence of Dr. Neeraj Mittal, Secretary (Telecom), and Shri Arvind Shrivastava, Secretary (Revenue). The agreement..